Literature DB >> 3044666

Effects of hyperinsulinaemia on the cardiovascular responses to graded hypovolaemia in normal and diabetic subjects.

A R Scott1, T Bennett, I A MacDonald.   

Abstract

1. Two experiments were carried out. The first with five normal male subjects was placebo controlled and single blind, each subject being studied on two occasions. Lower body subatmospheric pressure (LBSP) was used to assess the cardiovascular effects of graded hypovolaemia before and during either a hyperinsulinaemic, euglycaemic clamp or a placebo clamp using 0.9% (w/v) NaCl only. 2. During hyperinsulinaemia, resting systolic blood pressure rose and was accompanied by forearm vasodilatation. Forearm blood flow (FABF) and heart rate (HR) were higher at each level of LBSP during than before hyperinsulinaemia. In addition, hyperinsulinaemia was accompanied by a small increase in noradrenaline, but packed cell volume did not change. 3. In the second experiment, the effects of a hyperinsulinaemic euglycaemic clamp on the cardiovascular responses to LBSP were assessed in seven diabetic subjects with peripheral and autonomic neuropathy. 4. In contrast to the normal subjects, there was a slight fall in systolic blood pressure during the clamp but no effect was noted on HR or FABF. Mean arterial blood pressure was lower at each level of LBSP during hyperinsulinaemia compared with the pre-clamp period. Packed cell volume fell during the clamp and plasma noradrenaline rose. In one of the diabetic subjects, a precipitous fall in blood pressure occurred during hyperinsulinaemia when LBSP of 10 mmHg (1.3 kPa) was applied, this manoeuvre having been well tolerated before the clamp. 5. The mode of action of hyperinsulinaemia is not clear, but there was, however, no evidence that a fall in plasma volume had occurred.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044666     DOI: 10.1042/cs0750085

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

1.  The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects.

Authors:  C Berne; J Fagius; T Pollare; P Hjemdahl
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

2.  A carbohydrate meal attenuates the forearm vasoconstrictor response to lower body subatmospheric pressure in healthy young adults.

Authors:  M T Kearney; T A Stubbs; A J Cowley; I A Macdonald
Journal:  Clin Auton Res       Date:  1997-12       Impact factor: 4.435

3.  Haemodynamic and hormonal effects of two different oral glucose loads in normal human subjects.

Authors:  S Puvi-Rajasingham; B Wijeyekoon; P Natarajan; L P Watson; C J Mathias
Journal:  Clin Auton Res       Date:  1997-06       Impact factor: 4.435

4.  Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance.

Authors: 
Journal:  Hypertension       Date:  2002-11       Impact factor: 10.190

5.  Metabolic heat production and cardiovascular responses to an incremental intravenous infusion of adrenaline in healthy subjects.

Authors:  D G Maggs; I W Gallen; K Fone; I A Macdonald
Journal:  Clin Auton Res       Date:  1994-06       Impact factor: 4.435

6.  Insulin-induced increase in heart rate and its prevention by propranolol.

Authors:  A Siani; P Strazzullo; N Giorgione; A De Leo; M Mancini
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Exogenous insulin augments in healthy volunteers the cardiovascular reactivity to noradrenaline but not to angiotensin II.

Authors:  R O Gans; H J Bilo; W W von Maarschalkerweerd; R J Heine; J J Nauta; A J Donker
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

8.  Prevention by insulin treatment of endothelial dysfunction but not enhanced noradrenaline-induced contractility in mesenteric resistance arteries from streptozotocin-induced diabetic rats.

Authors:  P D Taylor; B B Oon; C R Thomas; L Poston
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.